TSC
ABUS icon

Two Seas Capital’s Arbutus Biopharma ABUS Stock Holding History

Two Seas Capital’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$83.5M Buy
18,557,543
+5,968,385
+47% +$26.1M 1.17% 14
2025
Q4 		$60.6M Buy
12,589,158
+1,597,897
+15% +$7.19M 1.25% 14
2025
Q3 		$49.9M Buy
10,991,261
+547,944
+5% +$2.01M 0.8% 14
2025
Q2 		$32.3M Buy
10,443,317
+977,361
+10% +$3.25M 0.54% 17
2025
Q1 		$33M Buy
9,465,956
+725,000
+8% +$2.42M 1.04% 13
2024
Q4 		$28.6M Buy
8,740,956
+353,568
+4% +$1.3M 2.47% 13
2024
Q3 		$32.3M Sell
8,387,388
-184,363
-2% -$707K 5.23% 5
2024
Q2 		$26.5M Buy
8,571,751
+729,824
+9% +$2.19M 4.3% 7
2024
Q1 		$20.2M Sell
7,841,927
-1,200,000
-13% -$3.11M 3.96% 3
2023
Q4 		$22.6M Buy
9,041,927
+761,109
+9% +$1.49M 5.52% 4
2023
Q3 		$16.8M Hold
8,280,818
– – 3.38% 3
2023
Q2 		$19M Buy
8,280,818
+816,094
+11% +$2.12M 4.16% 3
2023
Q1 		$22.6M Sell
7,464,724
-39,469
-0.5% -$111K 20.76% 2
2022
Q4 		$17.5M Buy
7,504,193
+1,850,276
+33% +$4.43M 16.61% 2
2022
Q3 		$10.8M Buy
5,653,917
+2,152,041
+61% +$5.07M 9.86% 5
2022
Q2 		$9.49M Buy
3,501,876
+1,302,807
+59% +$3.33M 12.35% 4
2022
Q1 		$6.55M Buy
2,199,069
+1,373,500
+166% +$4.2M 5.49% 3
2021
Q4 		$3.21M Buy
+825,569
New +$3.21M 2.46% 4

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Two Seas Capital's ABUS Position: Q1 2026 in Review

Two Seas Capital increased its Arbutus Biopharma (ABUS) stake by 47% in Q1 2026, buying an estimated $26.1M and bringing the position to 18,557,543 shares worth $83.5M. The position accounts for 1.17% of the portfolio, ranked #14.

Two Seas Capital first reported a position in ABUS in Q4 2021 and has held it in 18 quarters since. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Two Seas Capital held 18,557,543 shares of Arbutus Biopharma worth $83.5M as of Q1 2026.
  • Two Seas Capital bought 5,968,385 Arbutus Biopharma shares in Q1 2026, an estimated $26.1M.
  • Arbutus Biopharma made up 1.17% of Two Seas Capital's portfolio in Q1 2026, its #14 holding.
  • Two Seas Capital first reported a position in Arbutus Biopharma in Q4 2021 and has held it in 18 quarters since.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Two Seas Capital's 13F filing for Q1 2026, filed 15 May 2026.